GLAS Glass House Brands Inc.
Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods. The Retail segment owns, and operates retail cannabis stores, and dispensary operation management services. The Wholesale Biomass segment includes propagation, nursery, flowering canopy, dries, processes, and distributes cannabis biomass. The Cannabis-Related Consumer Packaged Goods segment manufactures, extracts, infuse, conversion, packaging, and distributes cannabis products. The company cultivates, manufactures, and distributes cannabis bulk flowers and trims to wholesalers; and consumer packaged goods to third-party retail stores in California. It also offers raw cannabis, cannabis oil, and cannabis consumer goods; edibles; flower jars and bags; single, multi-pack, and infused pre-rolls; tinctures; biomass for distributors; and online payment processing, in-store pickup and home delivery services for adult-use and medicinal-use customers. The company serves its cannabis products under the Glass House Farms, PLUS, Allswell, REEFORM, and Mama Sue brand names. Glass House Brands Inc. was founded in 2015 and is headquartered in Long Beach, California.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Glass House Brands (NYSE: GLAS)
›
Glass House Brands (NYSE: GLAS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 357 employees.
The shares were at 1.270 USD on 13 November 2026, down 82.4% over 52 weeks. Its 52-week range is 1.061 USD to 13.93 USD: the price is 90.9% below the high and 19.7% above the low.
Its market capitalisation is 119.69M USD.
Glass House Brands reports return on equity of -40.1%, an operating margin of -22.8% and revenue down 1.2% year over year.
Its debt exceeds its cash by 53.76M USD, a debt-to-equity ratio of 1.01. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 16 November 2026.